RxDoctor Payments Data

Christal House

Family · Monticello, GANPI 1568021038

Payments from drug & device makers

$11,008in general payments, 2019–2025

Across 630 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$837
  • Novo Nordisk$833
  • Corium, LLC$798
  • AstraZeneca$644
  • Bayer$621
  • plus $6K from 46 others

What the payments were for

  • Food & beverage$10,93599%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,008 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$36,788
Medicare patients
139
Services billed
856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$172,077
TrulicityDulaglutide45$58,182
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$51,226
MounjaroTirzepatide31$46,916
RexultiBrexpiprazole32$45,810
RybelsusSemaglutide34$43,418
FarxigaDapagliflozin Propanediol32$35,654
JardianceEmpagliflozin29$28,380
EliquisApixaban33$28,204
KerendiaFinerenone27$26,549
VraylarCariprazine Hcl17$24,500
MyrbetriqMirabegron38$22,995
LinzessLinaclotide38$21,197
GemtesaVibegron24$19,107
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$17,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$833$215,496176 claims
Lilly USA, LLCTrulicity, Mounjaro$837$105,09776 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Tradjenta, Combivent Respimat$270$66,29593 claims
AstraZenecaFarxiga, Breztri Aerosphere$644$53,23152 claims
GSKTrelegy Ellipta$300$51,22659 claims
AbbVieVraylar, Linzess, Synthroid$1,509$47,30385 claims
Otsuka America Pharmaceutical, Inc.Rexulti$348$45,81032 claims
PfizerEliquis$494$28,20433 claims
BayerKerendia$621$26,54927 claims
Astellas Pharma US IncMyrbetriq$253$22,99538 claims
Sumitomo Pharma America, Inc.Gemtesa$23$19,10724 claims
Johnson & JohnsonXarelto$61$12,18812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Monticello

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →